Amy M. Lin, Charles J. Ryan, Eric J. Small

Slides:

Advertisements

Similar presentations

Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.

Advertisements

The Microbiome and Cancer: Is the ‘Oncobiome’ Mirage Real? Ryan M. Thomas, Christian Jobin Trends in Cancer Volume 1, Issue 1, Pages (September 2015)

Auditory nerve disease and auditory neuropathy spectrum disorders Kimitaka Kaga Auris Nasus Larynx Volume 43, Issue 1, Pages (February 2016) DOI:

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Perimenopausal migraine in women with vasomotor symptoms E. Anne MacGregor Maturitas Volume 71, Issue 1, Pages (January 2012) DOI: /j.maturitas

The most efficient STR loci in forensic genetics in population of central Poland R. Jacewicz, M. Jedrzejczyk, J. Berent Forensic Science International:

The Survival Kit: Software to analyze survival data including possibly correlated random effects G. Mészáros, J. Sölkner, V. Ducrocq Computer Methods and.

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature María Teresa Martínez, José Alejandro Pérez-Fidalgo, Paloma Martín-Martorell,

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Critical Reviews in Oncology / Hematology

Eribulin—A review of preclinical and clinical studies

Gastric cancer Critical Reviews in Oncology / Hematology

Umesh K. Narta, Shamsher S. Kanwar, Wamik Azmi

Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer

Exercise issues in older cancer survivors

Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review Cloé Brami, Ting Bao, Gary Deng Critical.

Novel targets in gastric and esophageal cancer

Critical Reviews in Oncology / Hematology

Nicoletta Colombo, Martin Gore

Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions? Séverine Guiu, Anita Wolfer, William Jacot, Pierre.

Philipp Dahm, Ari D. Silverstein, Alon Z

Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force Silvio Monfardini,

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

The case for wider use of recombinant factor VIII concentrates

Critical Reviews in Oncology / Hematology

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer Sandro Pignata, Enrico.

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature Omar Abdel-Rahman,

Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead J. Carlijn Van Gaal, Eveline S.J.M. De Bont, Suzanne.

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey Lazzaro Repetto Critical.

Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review.

Mast cells in breast cancer angiogenesis

Genistein: Its role in metabolic diseases and cancer

Jonathan P. Evans, Paul A. Sutton, Boleslaw K. Winiarski, Stephen W

Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review.

A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC) Giorgio Arcangeli,

Volume 64, Pages e1-e3 (January 2017)

Abhimanyu Ghose, Ria Kundu, Tahir Latif

Critical Reviews in Oncology / Hematology

Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment Judith Maresch, Sebastian F. Schoppmann,

P. Therasse, S. Carbonnelle, J. Bogaerts

Olfa Baroudi, Amel Benammar-elgaaied

Clinically useful prognostic factors in acute myeloid leukemia

Long non-coding RNA CASC2 in human cancer

Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric.

Gwo Yaw Ho, Natasha Woodward, Jermaine I.G. Coward

Critical Reviews in Oncology / Hematology

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello Critical.

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer Miguel.

Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders Mai F. Tolba, Hany A.

Gerhard J. Molderings Critical Reviews in Oncology / Hematology

Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer Delmy Oliva, Mats Nilsson, Bengt-Åke Andersson,

What evidence is good evidence? A Masterclass in critical appraisal

Volume 55, Issue 3, Pages (March 2009)

Pediatric Intensive Care Treatment of Uncontrolled Status Epilepticus

Volume 152, Issue 1, Pages (January 2019)

Roy Hertz, M.D. (1909–2002): The cure of choriocarcinoma and its impact on the development of chemotherapy for cancer Jonathan P Yarris, B.S., Alan J.

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Volume 15, Issue 6, Pages (May 2014)

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Skin cancer epidemic in a wireless world

Increasing incidence of brain tumours in sparsely populated areas

Treatment of Colorectal Cancer

A forensic genetic approach to European fisheries enforcement

Proportion of continuous, intermittent, and limited (

Induction Therapy For Locally Advanced Thymoma

Genomic determinants of response to cytotoxic chemotherapy.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Presentation transcript:

Intermittent chemotherapy for metastatic hormone refractory prostate cancer Amy M. Lin, Charles J. Ryan, Eric J. Small Critical Reviews in Oncology / Hematology Volume 61, Issue 3, Pages 243-254 (March 2007) DOI: 10.1016/j.critrevonc.2006.10.002 Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 Intermittent vs. continuous chemotherapy for breast cancer. Study schema for Tormey et al. [7]. Abbreviations—Cyt: cyclophosphamide, MTX: methotrexate, 5FU: 5-fluorouracil, VCR: vincristine, Pred: prednisone, and Adria: adriamycin. Critical Reviews in Oncology / Hematology 2007 61, 243-254DOI: (10.1016/j.critrevonc.2006.10.002) Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 Intermittent vs. continuous chemotherapy for breast cancer. Study schema for Coates et al. [8]. Abbreviations—Adria: adriamycin, Cyt: cyclophosphamide, MTX: methotrexate, 5FU: 5-fluorouracil, Pred: prednisone, CR: complete response, PR: partial response, and SD: stable disease. Critical Reviews in Oncology / Hematology 2007 61, 243-254DOI: (10.1016/j.critrevonc.2006.10.002) Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions

Fig. 3 Intermittent vs. continuous chemotherapy for breast cancer. Study schema for Muss et al. [10]. Abbreviations—Cyt: cyclophosphamide, Adria: adriamycin, 5FU: 5-fluorouracil, MTX: methotrexate, CR: complete response, PR: partial response, and SD: stable disease. Critical Reviews in Oncology / Hematology 2007 61, 243-254DOI: (10.1016/j.critrevonc.2006.10.002) Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions

Fig. 4 Intermittent vs. continuous chemotherapy for breast cancer. Study schema for the French Epirubicin Study [11]. Abbreviations—Cyt: cyclophosphamide, Epi: epirubucin, 5FU: 5-fluorouracil, CR: complete response, PR: partial response, and SD: stable disease. Critical Reviews in Oncology / Hematology 2007 61, 243-254DOI: (10.1016/j.critrevonc.2006.10.002) Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions

Fig. 5 Intermittent vs. continuous chemotherapy for colorectal cancer. Study schema for Maughan et al. [12]. Abbreviations—5FU: 5-fluorouracil, CR: complete response, PR: partial response, and SD: stable disease. Critical Reviews in Oncology / Hematology 2007 61, 243-254DOI: (10.1016/j.critrevonc.2006.10.002) Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions